188 related articles for article (PubMed ID: 33137361)
21. Zinc: A Potential Antiviral Against Hepatitis E Virus Infection?
Kaushik N; Anang S; Ganti KP; Surjit M
DNA Cell Biol; 2018 Jul; 37(7):593-599. PubMed ID: 29897788
[TBL] [Abstract][Full Text] [Related]
22. FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis.
Qu C; Li Y; Li Y; Yu P; Li P; Donkers JM; van de Graaf SFJ; de Man RA; Peppelenbosch MP; Pan Q
Antiviral Res; 2019 Oct; 170():104588. PubMed ID: 31415805
[TBL] [Abstract][Full Text] [Related]
23. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway.
Zhang L; Jilg N; Shao RX; Lin W; Fusco DN; Zhao H; Goto K; Peng LF; Chen WC; Chung RT
J Hepatol; 2011 Aug; 55(2):289-98. PubMed ID: 21147189
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells.
Hirano K; Ichikawa T; Nakao K; Matsumoto A; Miyaaki H; Shibata H; Eguchi S; Takatsuki M; Ikeda M; Yamasaki H; Kato N; Kanematsu T; Ishii N; Eguchi K
Liver Transpl; 2008 Mar; 14(3):292-8. PubMed ID: 18306331
[TBL] [Abstract][Full Text] [Related]
25. Isocotoin suppresses hepatitis E virus replication through inhibition of heat shock protein 90.
Nimgaonkar I; Archer NF; Becher I; Shahrad M; LeDesma RA; Mateus A; Caballero-Gómez J; Berneshawi AR; Ding Q; Douam F; Gaska JM; Savitski MM; Kim H; Ploss A
Antiviral Res; 2021 Jan; 185():104997. PubMed ID: 33326835
[TBL] [Abstract][Full Text] [Related]
26. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
Todt D; Moeller N; Praditya D; Kinast V; Friesland M; Engelmann M; Verhoye L; Sayed IM; Behrendt P; Dao Thi VL; Meuleman P; Steinmann E
Antiviral Res; 2018 Sep; 157():151-158. PubMed ID: 30036559
[TBL] [Abstract][Full Text] [Related]
27. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro.
Nishiyama T; Kobayashi T; Jirintai S; Nagashima S; Primadharsini PP; Nishizawa T; Okamoto H
Antiviral Res; 2019 Oct; 170():104570. PubMed ID: 31362004
[TBL] [Abstract][Full Text] [Related]
28. Role of ISGF3 in modulating the anti-hepatitis B virus activity of interferon-alpha in vitro.
Zhang Q; Wang Y; Wei L; Jiang D; Wang JH; Rao HY; Zhu L; Chen H; Fei R; Cong X
J Gastroenterol Hepatol; 2008 Nov; 23(11):1747-61. PubMed ID: 17559358
[TBL] [Abstract][Full Text] [Related]
29. Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication.
Debing Y; Winton J; Neyts J; Dallmeier K
Antiviral Res; 2013 Oct; 100(1):98-101. PubMed ID: 23916729
[TBL] [Abstract][Full Text] [Related]
30. Antiviral Candidates for Treating Hepatitis E Virus Infection.
Netzler NE; Enosi Tuipulotu D; Vasudevan SG; Mackenzie JM; White PA
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885901
[TBL] [Abstract][Full Text] [Related]
31. Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions.
Guo H; Liu D; Liu K; Hou Y; Li C; Li Q; Ding X; Verstegen MMA; Zhang J; Wang L; Ding Y; Tang R; Pan X; Zheng K; van der Laan LJW; Pan Q; Wang W
Virol Sin; 2024 Feb; 39(1):123-133. PubMed ID: 37984761
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of STAT Pathway Impairs Anti-Hepatitis C Virus Effect of Interferon Alpha.
Zhao LJ; He SF; Liu Y; Zhao P; Bian ZQ; Qi ZT
Cell Physiol Biochem; 2016; 40(1-2):77-90. PubMed ID: 27855377
[TBL] [Abstract][Full Text] [Related]
33. Niclosamide inhibits hepatitis E virus through suppression of NF-kappaB signalling.
Li Y; Li P; He Q; Zhang R; Li Y; Kamar N; Peppelenbosch MP; de Man RA; Wang L; Pan Q
Antiviral Res; 2022 Jan; 197():105228. PubMed ID: 34929248
[TBL] [Abstract][Full Text] [Related]
34. ISG15 Modulates Type I Interferon Signaling and the Antiviral Response during Hepatitis E Virus Replication.
Sooryanarain H; Rogers AJ; Cao D; Haac MER; Karpe YA; Meng XJ
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724761
[TBL] [Abstract][Full Text] [Related]
35. Anti-hepatitis B virus activity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo.
Bingfa X; Qinglin F; Hui H; Canjun W; Wei W; Lihua S
Pharmacology; 2009; 83(6):323-32. PubMed ID: 19407486
[TBL] [Abstract][Full Text] [Related]
36. MxA is a positive regulator of type I IFN signaling in HCV infection.
Shi X; Jiao B; Chen Y; Li S; Chen L
J Med Virol; 2017 Dec; 89(12):2173-2180. PubMed ID: 28561372
[TBL] [Abstract][Full Text] [Related]
37. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon.
Debing Y; Emerson SU; Wang Y; Pan Q; Balzarini J; Dallmeier K; Neyts J
Antimicrob Agents Chemother; 2014; 58(1):267-73. PubMed ID: 24145541
[TBL] [Abstract][Full Text] [Related]
38. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
39. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection.
Kamar N; Rostaing L; Abravanel F; Garrouste C; Lhomme S; Esposito L; Basse G; Cointault O; Ribes D; Nogier MB; Alric L; Peron JM; Izopet J
Gastroenterology; 2010 Nov; 139(5):1612-8. PubMed ID: 20708006
[TBL] [Abstract][Full Text] [Related]
40. Interferon alpha-armed nanoparticles trigger rapid and sustained STAT1-dependent anti-viral cellular responses.
Pollok S; Ginter T; Günzel K; Pieper J; Henke A; Stauber RH; Reichardt W; Krämer OH
Cell Signal; 2013 Apr; 25(4):989-98. PubMed ID: 23333460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
